Dec 2, 2021 · 32m · a16z
B2C2B in Digital Health, a founder's playbook
Jay Rughani · 9m spoken Julie Yoo · 3m spoken Kate Ryder · 3m spoken Chris Hogue · 2m spoken Amanda Rees · 2m spoken Sajith Wickramasekara · 2m spoken Andrew Le · 1m spoken
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Hosted by a16z Bio's Julie Yoo and Jay Rughani, this video outlines a comprehensive founder playbook for the B2C2B go-to-market model in digital health. Featuring insights from prominent digital health CEOs, the presentation details how startups can generate organic consumer momentum and successfully transition into high-value enterprise sales.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 2.6 Guest teaching 3.6 Guest disagreement 0.8 The host pushing back 0.0
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 24:32 Andrew Le dismisses ROI calculators
Andrew Le contrarianly rejects conventional enterprise sales logic, asserting that buyers do not run detailed financial ROI calculations but rather look strictly at active user volume.
Hardest push from the host ▶ 29:48 Julie Yoo sets rigorous investment standardsJulie Yoo sets strict evaluation boundaries for B2C2B startups, insisting that consumer traction and dual-motion financing plans must meet clear criteria.
Biggest teaching moment ▶ 21:04 Sajith Wickramasekara on why end-user love isn't enough for B2B salesSajith Wickramasekara explains how Benchling initially failed selling directly to scientists who loved the product, educating listeners that enterprise conversion requires building central data aggregation value for executives.
The host holds their own ▶ 29:48 Julie Yoo demonstrates investment evaluation frameworkJulie Yoo demonstrates deep domain investment expertise by detailing the precise metrics and pipeline indicators a VC evaluates across the consumer and enterprise legs of a B2C2B business.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Opening Title Animation and Legal Disclosures | 3 | 0 | 0 | 0 | Hosts Julie Yoo and Jay Rughani present an overview of go-to-market evolutions in digital health, framing the shift from traditional software selling to B2C2B motions. The segment consists of structured host narration without host-guest friction. | |
| Flavors of B2C2B and Key Questions for Founders | 2 | 4 | 1 | 0 | Chris Hogue explains why traditional B2B2C models were forced on founders and how virtual care allows startups to invert the motion by acquiring patients direct-to-consumer while getting reimbursed via traditional coding stacks. | |
| Benefits, Defensibility, and Early Traction with Kate Ryder | 2 | 5 | 0 | 0 | Kate Ryder shares early growth tactics at Maven, detailing how giveaway marketing with brand partners provided 20,000 email leads to bootstrap consumer demand and demonstrate traction to investors before selling into enterprises. | |
| Building for Engagement and User Focus | 2 | 4 | 1 | 0 | Chris Hogue and Sajith Wickramasekara emphasize hyper-focused product development, advising founders to secure small, deeply engaged user cohorts rather than attempting broad platform builds without acute problem alignment. | |
| Navigating Consumer Pricing and Value Perception | 2 | 4 | 1 | 0 | Guests discuss the subtleties of consumer pricing in digital health, where Kate Ryder notes consumer confusion regarding insurance coverage versus cash pay and Amanda Rees warns that B2C pricing sets baseline expectations for B2B buyer conversations. | |
| Knowing When to Go B2B and Proving ROI | 2 | 5 | 1 | 0 | Amanda Rees and Sajith Wickramasekara articulate how to transition to B2B, highlighting six-month research outcome data and building enterprise-level single-source-of-truth features beyond individual end-user utility. | |
| Enterprise Selling and the Primacy of User Engagement | 2 | 5 | 2 | 0 | Andrew Le forcefully reframes enterprise buying dynamics, asserting that user engagement is the primary metric enterprise buyers care about and arguing that complex ROI calculators are a distraction. | |
| Balancing Dual Motions and Leveraging Professional Services | 2 | 5 | 1 | 0 | Guests examine the operational balance of maintaining dual go-to-market motions, with Sajith Wickramasekara explaining how highly configurable professional services prevent custom coding traps while guaranteeing enterprise success. | |
| Investor Evaluation Framework and Conclusion | 6 | 0 | 0 | 0 | Julie Yoo synthesizes the firm's investor evaluation framework across three clear pillars: consumer metrics, enterprise validation pipeline, and dual-motion capitalization plans. |
Statements from this episode (18)
Yoo: Bottom-up B2C2B sales model is playing out in healthcare
“It's kind of the healthcare version of a trend that we've seen play out in B to B software. So, you know, you might think about Slack or Zoom or Dropbox or these products that you as an individual user can obviously adopt, but then what these companies are the…”
US out-of-pocket health spending projected to reach $800B by 2026
“There's a recent report estimating nationwide out-of-pocket spending on health, i.e. Not reimbursed by insurance, is set to hit almost five hundred billion in the U.S. In 2021 and projected to grow to about eight hundred billion by 2026.”
Rughani: B2C2B lets health startups engage users before contracting payers
“While B to C to B can be more complex to execute, it gives startups the power to acquire and engage users directly without first contracting with the payer.”
Hogg: Payers now treat virtual care as a standard reimbursable service
“Now with virtual care we are a normal product. It is a normal clinical service, and it is in the eyes of a payer. They know how to pay for these types of services.”
Hogg: B2C2B pairs direct patient acquisition with traditional payer reimbursement
“So in a nutshell, the B to C to B motion is trying to control the growth through direct patient acquisition. So I can build up my own funnels and channels to acquire patients, but then still get paid by the traditional system of payers and employers.”
Jay Rughani: Dual B2C2B GTM creates long-term defensibility despite resource intensity
“The biggest challenge we hear about with B to C to B is that you're signing yourself up to execute two go-to-market motions in parallel with the limited resources of a startup. The upside though is that if you achieve a high engagement and stickiness in both m…”
Ryder: Maven collected 20,000 early email leads via giveaway marketing
“We launched it and then we got, I think, I don't know, something like 20,000 emails. And so all of a sudden we were like, wow, like 20,000 names of women from like-minded brands that now we can go market Maven too.”
Ryder: Maven drove conversion using 10-minute 'therapist speed dating' trials
“One of our earliest consumer campaigns that was really successful was called therapist speed dating. So what we did is we cut down our therapy appointments to 10 minute increments and then we would offer like free therapist speed dating to find the therapist f…”
Hogg: B2B2C digital health startups risk building for buyers instead of patients
“I think one of the challenges that folks got into with B to B to C is that that. Isn't so acute. And so you're able to build something that you can pitch well to buyers, but it might not be something that fits a problem that actual patients and users need to s…”
Wickramasekara: 100 deeply addicted users signal broader market demand
“If 10 people or a hundred people Were totally addicted to the software. Like that was a really good sign. Like, cause what are the chances that we found just the exact hundred people who would be completely addicted and there'd be no one else after that? So I …”
Ryder: Consumers resist cash-pay healthcare services due to insurance expectations
“Even though some of our early marketing was Maven is cheaper than the price of a copay. There was a lot of consumer confusion still around, wait, shouldn't my insurance pay for this? Like, and when it became a more transactional, like I just need a prescriptio…”
Rees: B2C pricing choices create price-explanation friction in enterprise sales
“Be mindful of whatever you put out as your B to C pricing, because you will have to explain the difference between B to C and B to C to B.”
Rughani: Start enterprise B2B sales after establishing repeatable usage patterns
“We generally recommend turning on enterprise when you see repeatable usage patterns among a core customer group through concrete data gathering.”
Rughani: Enterprise buyers expect digital health startups to present RCT ROI data
“Several digital health founders have told us that their enterprise buyers basically expected them to have a randomized control trial demonstrating the ROI before signing the partnership.”
Rees: Startups can use high user volume instead of clinical studies for B2B sales
“So maybe you haven't done a research study, but you have really, really big volume, and you can start collecting that data, or you can start saying like, I just have already have this existing base of many, many individuals. I think that's another way to posit…”
Benchling failed at enterprise sales until adding business-level data features
“And actually though, at first, like we really like struck out trying to sell anything to these companies. Like scientists have used Benchling in school. They liked it, but they weren't going to buy it. The business, like the value wasn't there. And that's when…”